UNSPSC 51342506: Abacavir sulfate

This classification denotes a reverse transcriptase inhibitor, in sulfate form, with the molecular formula 2C14H18N6O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J220T4J9Q2, chemically known as 2-cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-, sulfate (salt)(2:1), (1s,4r)- but more generally known as abacavir sulfate, which bears US NIH Compound Identifier 65141. The base compound, abacavir, also appears in succinate form, and is sometimes combined with lamivudine and zidovudine.

UNSPSC 51342506 Abacavir sulfate is a Commodity code nominally identifying a specific antiretroviral pharmaceutical product, but recent state and local procurement activity under this code does not reflect purchases of abacavir sulfate itself. Instead, the code appears in solicitations for a broad range of pharmaceuticals, medical supplies, and health-related products including naloxone, emergency medical equipment, generic multi-source pharmaceuticals, and over-the-counter products. The mismatch between the code's nominal scope and actual procurement activity suggests either inconsistent code assignment by issuing bodies or a broader taxonomic use of this Commodity classification. State and local governments buying under this code include county health departments, state health and human services commissions, and municipal fire departments, with issuing bodies spanning Florida, Texas, and Minnesota cooperatives serving multiple jurisdictions.

Recent activity shows Seminole County, Florida conducting an invitation to bid (IFB) for naloxone and drug deactivation systems with a response deadline of July 26, 2023; the City of Tampa issuing a sealed-bid solicitation for medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and a response deadline of March 13, 2026; the Texas Health and Human Services Commission posting a request for information (RFI) on direct-to-manufacturer pharmacy programs with a response deadline of April 3, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering an RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026. Geographic spread includes Florida, Texas, and the Minnesota cooperative serving Oregon and other participating jurisdictions. The lack of alignment between the code's pharmaceutical specificity and the diversity of actual procurements suggests caution in relying on this code alone for pipeline tracking; parallel monitoring of related pharmaceutical and medical-supply codes will likely yield higher-relevance opportunity flow.